Terumo sues over patent infringement; Device tax repeal petition grows;

 @FierceMedDev: PolyActiva pulls in $9.5M for intraocular implant work. Story | Follow @FierceMedDev

 @MarkHFierce: AutoGenomics aborted its second IPO attempt in a few years. The company promises #3, but we'll see. More | Follow @MarkHFierce

 @DamianFierce: In case you missed it over the weekend, Quintiles is finally kicking off the process of going public. News | Follow @DamianFierce

> Terumo Medical is suing two rivals in U.S. District Court, accusing both of patent infringement concerning the company's TR Band radial compression device. Release

> An online industry petition supporting repeal of the new device excise tax has already attracted more than 9,000 signatures. Story

> Total hip replacements tend to fail more in women than in men, according to a new Kaiser Permanente Southern California study published in the journal JAMA Internal Medicine. Release

> The second-generation micro-bypass Glaukos iStent inject significantly decreased intraocular pressure and lowers the number of required medications, according to a new study presented at the European Society of Cataract and Refractive Surgeons. Story

> Doctors don't counsel patients well enough about the long-term risks and emotional impact of living with an implantable cardioverter defibrillator to treat irregular heart rhythms, Saint Louis University scientists have found. Release

> A former Medtronic ($MDT) executive is the new chief technology officer of Decade of Discovery, a joint partnership between the University of Minnesota and the Mayo Clinic focused on defeating diabetes. Story

> Medical devices used for infants receiving neonatal intensive care may expose them to bisphenol A, an environmental endocrine disruptor that leaches out of polycarbonate plastics, according to a new Simmons College study. Story (reg. req.)

Biotech News

 @FierceBiotech: Pfizer axes CovX research unit and 100 jobs in San Diego. More | Follow @FierceBiotech

@JohnCFierce: Coronavirus, which killed 5 of the 12 people known to have been infected by it, is suited to spread easily in humans. Report | Follow @JohnCFierce

> Gilead races to FDA after hep C blockbuster hopeful scores 4th win in PhIII. Story

> Roche grabs rights to Chiasma's PhIII rare disease drug in $595M deal. Article

> Analysts assign Phytopharm to scrap heap after decisive Parkinson's failure. News

Pharma News

@FiercePharma: Novartis nixes $78M non-compete with Chairman Vasella amid frenzy of criticism from Swiss. Report | Follow @FiercePharma

@EricPFierce: Gilead recall raises question about Vistide stocks. Company tells providers to look to generic suppliers. Story | Follow @EricPFierce

@AlisonBFierce: Court: Sanofi is not liable to pay local capital gains tax for its 30B rupee acquisition of Indian vax maker Shantha. More | Follow @AlisonBFierce

> Novartis nabs another FDA-approved indication for everolimus. More

> Takeda preps for first Actos trial now opening in LA. News

Biotech Research News

> Antidepressant could reverse sickle cell disease. More

> Nicotinamide slows breast tumor growth in mice. Story

> Human stem cell trial set to begin in Japan. Item

> Compound could restore learning, memory in Angelman syndrome. Article

CRO News

> QPS swings into North Carolina with Hamner partnership. Story

> Charles River predicts strong 2013 despite Q4 slump. More

> With revenue rolling, AMRI looks to CDMO boom in 2013. Article

> Quintiles files IPO worth $600 million--or much more. News

Biotech IT News

> Genomics? There could be an app for that. Item

> Boehringer Ingelheim goes to Hungary for R&D software. More

> EU enters expensive race to map out brain secrets with computers. Article

> CLC bio capitalizes on surge in DNA sequencing. Story

Pharma Manufacturing News

> AMRI 'money pit' now money maker. Item

> GSK commits to continuous processing. More

> Gilead recalls some Vistide; supplies may be an issue. Article

> FDA lambastes Jamaican manufacturer over sterility, quality. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.